Amesite (AMST) Q3 2026 earnings summary

Executive summary

• Net loss of $2.05 million for the nine months ended March 31, 2026, improved from $2.69 million loss in the prior year period.

• Revenue for the nine months ended March 31, 2026, was $285,678, up from $54,700 year-over-year.

• Strategic pivot from academic to healthcare markets, focusing on AI-powered solutions like the NurseMagic app.

• Substantial doubt remains about the ability to continue as a going concern due to ongoing losses and limited cash.

Financial highlights

• Cash, cash equivalents, and restricted cash totaled $740,711 as of March 31, 2026, down from $2.43 million at June 30, 2025.

• Operating expenses for the nine months ended March 31, 2026, were $2.38 million, down from $2.80 million year-over-year.

• General and administrative expenses decreased to $1.68 million for the nine months, compared to $1.87 million prior year.

• Technology and content development expenses fell to $402,000 from $524,000 year-over-year.

• Sales and marketing expenses decreased to $299,000 from $411,000 year-over-year.

Outlook and guidance

• Management cannot assure profitability in the near term and expects continued net losses and cash usage.

• Plans to generate cash through financing transactions, including equity offerings, but success is uncertain.